

## SAFE HEALTHCARE FOR ALL



# The Rapid Response Podcasts



**COVID-19 Updates: What We Know Now** 

Releases monthly

#### **Newest Episodes:**

- SHEA Spring 2022 Recap
- CDC Guidance & Influence on COVID



**COVID-19 Allies in Infection Prevention** 





#### **SHEA COVID-19 Resources:**





This program is designed to give US hospital epidemiologists who oversee infection control programs the skills, knowledge, and tools to provide effective leadership during facility-level outbreaks and large-scale public health emergencies.

- Simulations
- Tools Kits
- On-demand Webinars
- On-demand Workshop Sessions
- Expert Guidance on Incident Management and HICs, Crisis Strategies, Communication Guidance and Much More

www.ortp.shea-online.org



## **COVID-19 Real-Time Learning Network**



#### **Specialty Society Collaborators:**

- American Academy of Family Physicians
- American Academy of Pediatrics
- American College of Emergency Physicians
- American College of Physicians
- American Geriatrics Society
- American Thoracic Society
- Pediatric Infectious Diseases Society
- Society for Critical Care Medicine
- Society for Healthcare Epidemiology of America
- Society of Hospital Medicine
- Society of Infectious Diseases Pharmacists

With funding from the Centers for Disease Control and Prevention, IDSA has launched the COVID-19 Real Time Learning Network, an online community that brings together information and opportunities for discussion on latest research, guidelines, tools and resources from a variety of medical subspecialties around the world.

www.COVID19LearningNetwork.org
@RealTimeCOVID19 | #RealTimeCOVID19



#### WE'VE UPDATED ALL MODULES!

The SHEA Prevention Course in HAI Knowledge and Control (Prevention CHKC) is online, interactive, and designed to give frontline personnel what they need to know to prevent healthcare-associated infections (HAIs).


Access for **FREE** using promo code **TOWNHALL**at checkout!





SAFE HEALTHCARE FOR ALL

# ICHE Journal – Fast Tracking COVID Article Submissions




Infection Control & Hospital Epidemiology publishes scientifically authoritative, clinically applicable, peer-reviewed research on control and evaluation of the transmission of pathogens in healthcare institutions and on the use of epidemiological principles and methods to evaluate and improve the delivery of care. Major topics covered include infection control practices, surveillance, antimicrobial stewardship, cost-benefit analyses, resource use, occupational health, and regulatory issues.

www.cambridge.org/iche



#### **ASHE JOURNAL**



High quality articles across the full spectrum of antimicrobial stewardship and healthcare epidemiology.

**Exceptional author experience** through constructive peer review, competitive turnaround times, immediate online publication, a streamlined production process, and social media promotion.

Global, open access journal, bringing the widest possible impact, reach and discoverability of your research.

www.cambridge.org/ashe





# SEE YOU NEXT YEAR!

We hope to see you in Seattle, Washington for SHEA Spring 2023 April 12-14.





# **Important Dates:**

- Abstract & Travel Award Submission Deadline May 4
- Case Submission Deadline May 4
- Registration is scheduled to open for members May 3
   & nonmembers on May 31.

Join Us LIVE in Washington, DC Oct. 19-23, 2022





#### In Case of Technical Difficulties:

#### • Audio:

- Select one form of audio only (computer speakers or telephone connection)
- For full participation, you will need to join by computer

#### If you are having trouble joining:

- Use the emailed invitation to join via the URL, or call in with the provided phone numbers
- https://support.zoom.us



## **Webinar Recording Access:**



This webinar will be recorded and uploaded to LearningCE's Rapid Response Program



Streaming Live on SHEA's Facebook page




#### **Useful Features:**



- Chat: Talk to each other or ask SHEA Staff questions if you are having technical difficulties
- **Q&A**: Type in your question to be read aloud by SHEA Staff and answered by the Panelists




# REPORTED COVID-19 CASES IN THE UNITED STATES Cumulative Cases – 81,260,672



Increased by 49% from two weeks earlier

Source: New York Times 5-1-22

#### **US COVID-19 HOTSPOTS**




February 6, 2022

May 1, 2022




#### **CDC COVID-19 COMMUNITY LEVELS**



Source - https://covid.cdc.gov/covid-data-tracker/#county-view?list\_select\_state=all\_states&list\_select\_county=all\_counties&data-type=CommunityLevels&null=CommunityLevels


# HOSPITALIZATIONS AND ICU ADMISSIONS FOR COVID-19 IN THE UNITED STATES



Hospitalizations Essentially Unchanged from two weeks earlier

Source: New York Times 5-1-22


# COVID-19 DEATHS IN THE UNITED STATES Cumulative Deaths – 989,678



28% decrease from two weeks earlier


Source: New York Times 5-1-22

#### Daily COVID-19 Vaccinations in the United States



Source: Our World in Data 4-30-22


#### **COVID-19 VACCINATIONS IN THE UNITED STATES**



Source: Our World in Data 4-30-22

#### **COVID-19 BOOSTER DOSES IN THE UNITED STATES**

#### **CUMULATIVE DOSES ADMINISTERED 100.51 M**



#### This Week's COVID-19 News

- 1. A **JAMA Open Network** paper found that the risk of Guillain-Barré Syndrome was not increased with either mRNA vaccine but was slightly increased with the increased with the Johnson and Johnson vaccine.
- 2. An opinion piece in **JAMA Health Forum** by Joshua Sharfstein discussed how to manage false information about the pandemic.
- 3. A report in the CDC's **Morbidity and Mortality Weekly Report** analyzed surveillance data that estimated that 60% of Americans and 75 % of American children have had active COVID infection..
- 4. A **JAMA Internal Medicine** paper found that antigen test sensitivity was 64% and 84% when compared with same-day RT-PCR and viral culture, respectively in a cohort of 225 PCR positive patients.
- 5. A paper in **JAMA Cardiology** found that COVID vaccines offered significant protection against COVID infection and mortality for heart transplant patients, despite their immunosuppressive regimens.
- 6. A report in **Science Immunology** found that **t**wo doses of the mRNA SARS-CoV-2 vaccines are less effective at inducing neutralizing antibodies against the Omicron variant, but a third dose or breakthrough infection rescues those poor antibody responses.
- 7. A **MedRxIV** preprint found that Omicron infections feature lower peak viral RNA and shorter clearance phases than Delta infections on average, and that the infectious period for Omicron is heterogeneous, with clear implications for isolation policies.
- 8. Moderna filed data with FDA this week to request Emergency Use Authorization for its vaccine in children under the age of six.

  \*\*References available in the chat\*\*

### **Panelists:**



**Dr. David Henderson** *NIH Consultant* 



**Dr. Sarah Haessler** *Baystate Health* 



**Dr. Kristina Bryant** *University of Louisville* 



**Dr. David Weber** UNC School of Medicine



# COVID-19 Vaccines for Kids < 5 years

**The Saga Continues** 

# The Pfizer-BioNTech Story

#### **December 2021**

Pfizer-BioNTech announce clinical trial results in kids < 5

#### Immunogenicity analysis:

- Non-inferiority criteria met for 6 -24-month-olds but not 2-5-year-olds
- Study of 3<sup>rd</sup> dose announced

# The Pfizer-BioNTech Story

#### **December 2021**

Pfizer-BioNTech announce clinical trial results in kids < 5

#### **February 1, 2022**

Pfizer-BioNTech announce rolling submission to FDA

#### Immunogenicity analysis:

- Non-inferiority criteria met for 6 -24-month-olds but not 2-5-year-olds
- Study of 3<sup>rd</sup> dose announced

- Data on 2- dose series submitted at FDA request
- VRBPAC meeting scheduled February 15th

# The Pfizer-BioNTech Story

#### **December 2021**

Pfizer-BioNTech announce clinical trial results in kids < 5

#### **February 1, 2022**

Pfizer-BioNTech announce rolling submission to FDA

#### February 11, 2022

Pfizer-BioNTech notify FDA of "additional findings"

#### Immunogenicity analysis:

- Non-inferiority criteria met for 6 -24-month-olds but not 2-5-year-olds
- Study of 3<sup>rd</sup> dose announced

- Data on 2- dose series submitted at FDA request
- VRBPAC meeting scheduled February 15th

- FDA postpones VRBPAC meeting waiting for 3<sup>rd</sup> dose data
- "Disappointing effectiveness against Omicron"

# The Moderna Story

#### March 2022

Moderna announces clinical trial results in kids < 6

- "Strong immune response"
- "Generally well-tolerated"

# KidsCove Study

	6 to 23-month-olds	2 to 5-year-olds
Effectiveness (symptomatic COVID-19)*	51% (95% CI: 21-69)	37% (95% CI: 13-54)
SARS-CoV-2 neutralizing Ab GMR	1.3 (95% CI 1.1, 1.5)	1.0 (95% CI 0.9, 1.2)
Fever ≥ 38	17%	14.6%
Fever > 40	0.2%	0.2%

<sup>\*</sup>Confirmed by PCR

# The Moderna Story

#### **March 2022**


Moderna announces clinical trial results in kids < 6 years


#### April 28, 2022

Moderna asks FDA to expand EUA to kids 6 m to 5 years

- "Strong immune response"
- "Generally well-tolerated"


# FDA to Discuss Pediatric COVID-19 Vaccines, June 2022





https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/children-and-covid-19-vaccination-trends/#:~:text=About%2018.5%20million%20children%205,66%25%20receiving%20their%20first%20dose.

## 3 in 4 U.S. Children Have Had COVID-19



m?s cid=mm7117e3 w